Use access key #2 to skip to page content.
$7.86 -0.12 (-1.50%)
8/21/2008 4:00 PM

Array BioPharma, Inc. (ARRY)

CAPS Rating:
**

A biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases.

View Ticker Page (ARRY)

Results 1 - 10 of 14 :   12

Recs

7

Avatar ForceMajeure26 (73.75) Submitted: 3/03/08 2:16 PM : Outperform Start Price: $6.44 ARRY Score: 25.90

What we have in Array BioPharma is what we see in Exelixis - only a year two earlier. And if there is a "safer" way for most of us to play the biotech sector it is to get in very early with small amounts and add over time in small pieces.
The reason ...

Report this Post Replies: 0 | Reply | Permalink

Recs

3

Avatar BIGJIMT (91.60) Submitted: 4/18/07 9:30 PM : Outperform Start Price: $13.18 ARRY Score: -27.60

PRODUCT PIPELINE AND HIRING OF DR,SPECTOR TO SEE TO IT THAT THE DRUGS HAVE A BETTER CHANCE OF APPROVAL WITH HIS BACKGROUND. FORMER EMPLOYEE OF GLAXO.
Dr. Spector served as Director of GlaxoSmithKline’s Exploratory Medical Sciences in Oncology, w...

Report this Post Replies: 0 | Reply | Permalink

Recs

1

Avatar wannabwriter (71.49) Submitted: 10/02/06 4:24 PM : Outperform Start Price: $8.67 ARRY Score: -5.03

New cures are right around the corner. Hopefully ARRY will make a right turn.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

Avatar Terapixel (92.86) Submitted: 2/08/08 2:19 PM : Outperform Start Price: $5.59 ARRY Score: 44.51

They've got a legitimate six-drug pipeline - scooping up at 52-week low.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

Avatar bsmith47 (56.88) Submitted: 4/17/08 11:41 AM : Outperform Start Price: $6.74 ARRY Score: 22.50

biotech darling will be bought out eventually by a big pharma for growth.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

Avatar tomk0508 (93.04) Submitted: 2/04/08 12:22 AM : Outperform Start Price: $6.49 ARRY Score: 29.31

This is an interesting small cap company with a decent drug pipeline as well as some very intriguing technology for drug development. It is not clear that they have a winner in the pipeline yet but they do have one of the best drug development platf...

Report this Post Replies: 0 | Reply | Permalink

Recs

0

Avatar PIcolano (81.72) Submitted: 12/21/07 3:38 PM : Outperform Start Price: $8.67 ARRY Score: 4.29

The depth of Array's pipeline is similar to Exelexis' pipeline, and should pay off handsomely for both companies over the long haul...

Report this Post Replies: 0 | Reply | Permalink

Recs

0

Avatar scampbel131 (99.69) Submitted: 12/14/07 2:01 PM : Outperform Start Price: $11.21 ARRY Score: -16.22

This one may take awhile to play out, but it is worth the risk to get in now.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

Avatar SavvyMoneyMan (43.55) Submitted: 10/17/07 4:28 PM : Outperform Start Price: $11.95 ARRY Score: -17.51

I decided to Bail on Excel after the failed drug trial so I ended that pick. Then the RuleBreaker newsletter gave me another drug company to replace excel. I really like what rulebreaker says, subscribe to get the details.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

Avatar RNZ100 (50.80) Submitted: 10/02/07 8:50 PM : Outperform Start Price: $10.56 ARRY Score: -8.66

If Celgene believes in them, then so do I!!

Report this Post Replies: 0 | Reply | Permalink

Featured Broker Partners